Want to see IN:CAPLIPOINT full AI Analyst Report?
CAPLIPOINT Stock Chart & Stats
₹1845.95
-₹76.70(-2.97%)
At close: 4:00 PM EST
₹1845.95
-₹76.70(-2.97%)
Day’s Range― - ―
52-Week Range₹1,502.45 - ₹2,700.00
Previous CloseN/A
Volume128.91K
Average Volume (3M)3.75K
Market Cap
₹191.47B
Enterprise Value₹104.83K
Total Cash (Recent Filing)₹10.07B
Total Debt (Recent Filing)₹46.10M
Price to Earnings (P/E)29.0
Beta1.31
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)84.36
Shares Outstanding76,011,696
10 Day Avg. Volume2,866
30 Day Avg. Volume3,752
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)3.19
Price to Sales (P/S)5.23
P/FCF Ratio33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)97
Revenue Forecast (FY)₹25.01B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained revenue growth indicates durable demand for the company’s generic formulations and effective execution across domestic and export markets. Continued portfolio expansion and established distribution channels can support ongoing scale and recurring product sales.
Strong ProfitabilityHealthy gross and net margins demonstrate that Caplin Point captures meaningful value from formulation manufacturing, registrations and overseas distribution. This profitability provides internal funding capacity for product launches, regulatory work and manufacturing expansion.
Conservative Balance SheetMinimal leverage limits financial risk and preserves flexibility to invest through industry cycles without depending heavily on external funding. Expanding equity and assets also indicate retained earnings and balance-sheet compounding over time.
Bears Say
Uneven Free Cash Flow ConversionAlthough operating cash flow is positive and improving, inconsistent conversion from earnings to free cash flow suggests working-capital or investment swings. This can reduce the predictability of funds available for expansion, acquisitions or shareholder returns.
Margin VolatilityRecent margin variability may reflect changing product mix, input costs, pricing pressure or market conditions in generic pharmaceuticals. If sustained, compression could limit earnings growth even while revenue continues expanding.
Potential ROE ModerationA rapidly growing equity base strengthens solvency but can dilute return metrics if profit growth does not keep pace. Lower capital efficiency could gradually reduce the company’s ability to compound shareholder returns at its historical rate.
Caplin Point Laboratories Limited News
CAPLIPOINT FAQ
What was Caplin Point Laboratories Limited’s price range in the past 12 months?
Caplin Point Laboratories Limited lowest stock price was ₹1502.45 and its highest was ₹2700.00 in the past 12 months.
What is Caplin Point Laboratories Limited’s market cap?
Caplin Point Laboratories Limited’s market cap is ₹191.47B.
When is Caplin Point Laboratories Limited’s upcoming earnings report date?
Caplin Point Laboratories Limited’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Caplin Point Laboratories Limited’s earnings last quarter?
Caplin Point Laboratories Limited released its earnings results on Aug 12, 2026. The company reported ₹23.3 earnings per share for the quarter, the consensus estimate of ₹23.3 by ₹0.
Is Caplin Point Laboratories Limited overvalued?
According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued.
Does Caplin Point Laboratories Limited pay dividends?
Caplin Point Laboratories Limited pays a Quarterly dividend of ₹4 which represents an annual dividend yield of 0.28%. See more information on Caplin Point Laboratories Limited dividends here
What is Caplin Point Laboratories Limited’s EPS estimate?
Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caplin Point Laboratories Limited have?
Caplin Point Laboratories Limited has 76,011,696 shares outstanding.
What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?
Caplin Point Laboratories Limited reported an EPS of ₹23.3 in its last earnings report, expectations of ₹23.3. Following the earnings report the stock price went down -5.676%.
Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?
Currently, no hedge funds are holding shares in IN:CAPLIPOINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive product portfolio encompasses a broad spectrum of pharmaceutical dosage forms, including various types of injections (liquid, lyophilized, IV infusions, powder for injection), oral preparations (tablets, liquid orals, capsules, softgel capsules, dry syrups), specialized applications (ophthalmic products, suppositories and ovules), and topical treatments (topicals, dermo cosmetics, inhalers). Beyond manufacturing, the company also manages an e-commerce platform named QueTenX. Established in 1990, Caplin Point Laboratories maintains its headquarters in Chennai, India.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Granules India Limited
―
Jubilant Pharmova Limited
―
Piramal Pharma Limited
―
Strides Pharma Science Ltd
―